Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Marker gene polymorphisms in hyperkinetic disorder--predictors of clinical response to treatment with methylphenidate?

Neuroscience letters - 2 Nov 2001

Seeger G, Schloss P, Schmidt M H

Abstract excerpt

Gene polymorphisms of the dopamine D4 receptor (DRD4) and serotonin transporter (5-HTT) are under discussion as potential genetic risk factors for hyperkinetic disorder (HD). In this disorder, treatment with the psychostimulant methylphenidate (MPH; Ritalin) induces calming effects and amelioration in only 70% of the patients. MPH blocks the reuptake of dopamine, thus enhancing synaptic dopamine which in turn...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Attention Deficit Disorder with Hyperactivity
Share to Central Nervous System Stimulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Membrane Transport Proteins

Share to Methylphenidate

Share to Prolactin

Share to Receptors, Dopamine D2

Share to Receptors, Dopamine D4

Share to Serotonin Plasma Membrane Transport Proteins

Source

Identifiers

PMID: 11684336
DOI: 10.1016/s0304-3940(01)02253-4

Genes

DRD4
HTT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Marker gene polymorphisms in hyperkinetic disorder--predictors of clinical response to treatment with methylphenidate?PMID 11684336Read ↗

DRD4 48 bp multiallelic variants as age-population-specific biomarkers in attention-deficit/hyperactivity disorder.Semantic proximity Read ↗

No significant association between genetic variants in 7 candidate genes and response to methylphenidate treatment in adult patients with ADHD.Semantic proximity Read ↗

Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.Semantic proximity Read ↗

Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD.Semantic proximity Read ↗

Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients.Semantic proximity Read ↗

A candidate gene investigation of methylphenidate response in adult attention-deficit/hyperactivity disorder patients: results from a naturalistic study.Semantic proximity Read ↗

Dopaminergic and noradrenergic gene polymorphisms and response to methylphenidate in korean children with attention-deficit/hyperactivity disorder: is there an interaction?Semantic proximity Read ↗

DRD4 exon 3 genotype and ADHD: Randomised pharmacodynamic investigation of treatment response to methylphenidate.Semantic proximity Read ↗

Pharmacogenetics of methylphenidate response and tolerability in attention-deficit/hyperactivity disorder.Semantic proximity Read ↗

Functional polymorphism within the promotor of the serotonin transporter gene is associated with severe hyperkinetic disorders.Semantic proximity Read ↗

Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children.Semantic proximity Read ↗

Response to methylphenidate is not influenced by DAT1 polymorphisms in a sample of Brazilian adult patients with ADHD.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.